Foamix pharmaceuticals ltd. (FOMX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
REVENUES (Note 13b)

443

3,595

3,669

5,527

849

5,414

1,404

1,086

COST OF REVENUES

-

-

13

59

70

527

453

491

GROSS PROFIT

443

3,595

3,656

5,468

779

4,887

951

595

OPERATING EXPENSES:
Research and development

51,202

64,474

57,779

25,897

10,680

3,557

1,086

1,202

Selling, general and administrative

45,114

14,013

11,491

9,221

7,029

2,964

1,221

953

TOTAL OPERATING EXPENSES

96,316

78,487

69,270

35,118

17,709

6,521

2,307

2,155

OPERATING LOSS

-95,873

-74,892

-65,614

-29,650

-16,930

-1,634

-1,356

-1,560

FINANCE INCOME (Note 13c)

1,672

985

1,134

701

452

-9,844

-1,075

-609

FINANCE EXPENSES (Note 13c)

1,153

44

71

-

-

-

-

-

LOSS BEFORE INCOME TAX

-95,354

-73,951

-64,551

-28,949

-16,478

-11,478

-2,431

-

INCOME TAX (Note 12)

-176

212

1,164

387

39

6

0

0

NET LOSS FOR THE YEAR

-95,178

-74,163

-65,715

-29,336

-16,517

-11,484

-2,431

-2,169

LOSS PER SHARE BASIC AND DILUTED

1.66

1.70

1.76

0.91

0.58

0.79

0.22

0.20

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS

57,292

43,660

37,376

32,263

28,229

14,512

11,285

11,003